Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer
dc.contributor.author | Fu, Zheng | en_US |
dc.contributor.author | Kitagawa, Yasuhide | en_US |
dc.contributor.author | Shen, Ronglai | en_US |
dc.contributor.author | Shah, Rajal B | en_US |
dc.contributor.author | Mehra, Rohit | en_US |
dc.contributor.author | Rhodes, Daniel R. | en_US |
dc.contributor.author | Keller, Peter J. | en_US |
dc.contributor.author | Mizokami, Atsushi | en_US |
dc.contributor.author | Dunn, Rodney L. | en_US |
dc.contributor.author | Chinnaiyan, Arul M. | en_US |
dc.contributor.author | Yao, Zhi | en_US |
dc.contributor.author | Keller, Evan T. | en_US |
dc.date.accessioned | 2007-03-19T17:26:19Z | |
dc.date.available | 2007-03-19T17:26:19Z | |
dc.date.issued | 2006-02-15 | en_US |
dc.identifier.citation | Fu, Zheng; Kitagawa, Yasuhide; Shen, Ronglai; Shah, Rajal; Mehra, Rohit; Rhodes, Daniel; Keller, Peter J.; Mizokami, Atsushi; Dunn, Rodney; Chinnaiyan, Arul M.; Yao, Zhi; Keller, Evan T. (2006)."Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer." The Prostate 66(3): 248-256. <http://hdl.handle.net/2027.42/49524> | en_US |
dc.identifier.issn | 0270-4137 | en_US |
dc.identifier.issn | 1097-0045 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/49524 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16175585&dopt=citation | en_US |
dc.description.abstract | BACKGROUND Diminished expression of Raf kinase inhibitor protein (RKIP), an inhibitor of the Raf signaling cascade, promotes prostate cancer (PCa) metastasis in a murine model, suggesting that it is a metastasis suppressor gene. However, the prognostic significance of RKIP expression and its association with metastasis in PCa patients is unknown. METHODS To investigate RKIP protein expression is a prognostic marker in PCa we performed immunohistochemical staining for RKIP expression in tissue microarrays consisting of 758 non-neoplastic prostate tissues, primary tumors and metastases from 134 PCa patients. The Cox proportional-hazards model was used to adjust for covariates including Gleason score, tumor volume, tumor weight, clinical stage, digital rectal exam findings, serum PSA level and surgical margins. RESULTS RKIP expression was low in approximately 5%, 48%, and 89%of non-neoplastic prostate, primary tumors and metastases, respectively. Low RKIP expression in primary tumors was a strong positive predictive factor for PCa recurrence based on PSA levels. In patients whose primary tumors expressed high RKIP levels, the 7-year PSA recurrence rate was < 10%; whereas in patients with tumors with low RKIP expression the recurrence rate was 50% ( P < 0.001). Multivariate analysis revealed RKIP was an independent prognostic factor ( P < 0.001). CONCLUSION In contrast to increased expression of pro-tumorigenic genes, these results demonstrate decreased protein expression of a gene, for example, RKIP, can serve as a prognostic marker in PCa patients. © 2005 Wiley-Liss, Inc. | en_US |
dc.format.extent | 215122 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan ; Room 5304, CCGC building, 500 E. Medical Center Dr., University of Michigan, Ann Arbor, MI 48109-0940. | en_US |
dc.contributor.affiliationother | Department of Urology, Kanazawa University, Kanazawa City, Japan | en_US |
dc.contributor.affiliationother | Department of Urology, Kanazawa University, Kanazawa City, Japan | en_US |
dc.contributor.affiliationother | Department of Immunology, Tianjin Medical University, Tianjin, China | en_US |
dc.identifier.pmid | 16175585 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/49524/1/20319_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/pros.20319 | en_US |
dc.identifier.source | The Prostate | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.